AIDS activists and others are asked to leave the lobby during a protest highlighting pharmaceutical drug pricing. AP Photo/Craig Ruttle, File
Martin Shkreli, the 32-year-old hedge fund and pharmaceutical industry guru who alienated large swaths of America by dramatically jacking up the price of a life-saving drug this September, was arrested by the FBI at his home in Manhattan early Thursday morning, as Bloomberg reports.
Shkreli first rose to national prominence when he raised the price of Daraprim, a drug that treats toxoplasmosis, from $13.50 to $750 overnight. The move drew condemnations from across the political spectrum, as well as the scrutiny of Congress, but after briefly suggesting he would walk back the price hike, Shkreli decided to go ahead with it. He even teased plans to acquire the rights to—and significantly raise the price of—another infectious disease treatment earlier this month. Read the rest of this entry »
The ABC News star, host to “Good Morning America (GMA)” and “This Week with George Stephanopoulos,” is seen in a piece of street art tweaking him for a series of donations totaling $75,000 to the Clinton Foundation. Stephanopoulos appears next to Hillary Clinton, her arm draped over him, and the image caption dubs him her “Pay Pal.”
Stephanopoulos, who used to work in Bill Clinton’s White House, did not disclose his donations to the Clinton Foundation when discussing that very subject during a hostile interview with Breitbart News Senior Editor-at-Large Peter Schweizer.
Schweizer’s book Clinton Cash alleges that during Hillary’s time as Secretary of State, the Clintons accepted sizable donations to the Clinton Foundation seemingly in exchange for favorable U.S. deals with foreign governments…(read more)
From July, 2012, Eugene Robinson writes: This is an amazing accomplishment, especially because it wasn’t supposed to be possible.
Before PEPFAR, the conventional wisdom was that the drug-treatment regimens that were saving lives in developed countries would not work in Africa. Poor, uneducated people in communities lacking even the most basic infrastructure could not be expected to take the right pill at the right time every day. When the drugs are taken haphazardly, the virus mutates and becomes resistant. Therefore, this reasoning went, trying to administer antiretroviral treatment in poor African countries might actually be worse than doing nothing at all.
The Bush administration rejected these arguments, which turned out to be categorically wrong.
Africans are every bit as diligent about taking their HIV medications as are Americans or other Westerners. While there has been a “modest, contained and not alarming” rise in resistance to one class of drugs, according to a World Health Organization researcher who presented a study at this week’s AIDS conference, scientists no longer envision a nightmare scenario in which drug-resistant strains of the virus run rampant.